Concepedia

Interferon Alpha-2b Therapy

Interferon Alpha-2b Therapy is a targeted biological treatment modality within the class of immunotherapeutic interventions, distinguished by the topical or intralesional administration of recombinant interferon alpha-2b to modulate the immune response and inhibit neoplastic cell proliferation in ocular surface and anterior segment neoplasia.

2.7K

Publications

164.4K

Citations

14.3K

Authors

2.9K

Institutions

Publications per year

2017–2026

186

Parents

Publications

2.7K

Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C

John G. McHutchison, Stuart C. Gordon, Eugene R. Schiff et al. · New England Journal of Medicine · 1998 · 3.5K citations · Full text

, , +16

Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus

Thierry Poynard, Patrick Marcellin, Samuel S. Lee et al. · The Lancet · 1998 · 2.3K citations

, , +17

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

Bernard Escudier, P. Koralewski, Alain Ravaud et al. · The Lancet · 2007 · 2.2K citations

, , +16

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

J M Kirkwood, M H Strawderman, Marc S. Ernstoff et al. · Journal of Clinical Oncology · 1996 · 2.1K citations

, , +17

Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell Cancer

Robert C. Flanigan, Sydney E. Salmon, Brent A. Blumenstein et al. · New England Journal of Medicine · 2001 · 1.7K citations

, , +16

1–5 of 2.7K

Authors

14.3K

  1. JM
    John M. Kirkwood

    UPMC Hillman Cancer Center, United States

    49 publications · 6.8K citations

    31

    h-index

  2. MB
    Michael B. Atkins

    Beth Israel Deaconess Medical Center, United States

    18 publications · 2.8K citations

    18

    h-index

  3. SZ
    Stefan Zeuzem

    Goethe University Frankfurt, Germany

    19 publications · 4.9K citations

    17

    h-index

  4. RD
    Reinhard Dummer

    University Hospital of Zurich, Switzerland

    18 publications · 2K citations

    17

    h-index

  5. JK
    Janice K. Albrecht

    Merck & Co., Inc., Rahway, NJ, USA (United States), United States

    18 publications · 9.4K citations

    16

    h-index

1–5 of 14.3K

Institutions

2.9K

  1. The University of Texas MD Anderson Cancer Center

    Houston, United States

    41 h-index

    414 publications

    41.1K citations

  2. Roche (Switzerland)

    Basel, Switzerland

    27 h-index

    103 publications

    9.9K citations

  3. Medizinische Hochschule Hannover

    Hanover, Germany

    26 h-index

    136 publications

    11.1K citations

  4. University of Miami

    Coral Gables, United States

    25 h-index

    116 publications

    10.3K citations

  5. National Institutes of Health

    Bethesda, United States

    25 h-index

    106 publications

    9.4K citations

  6. National Cancer Institute

    Bethesda, United States

    25 h-index

    120 publications

    12.5K citations

  7. Memorial Sloan Kettering Cancer Center

    New York, United States

    24 h-index

    105 publications

    10.4K citations

  8. Goethe University Frankfurt

    Frankfurt am Main, Germany

    21 h-index

    64 publications

    7.6K citations

1–8 of 2.9K

Venues

  1. Journal of Clinical Oncology

    165 publications · 22.9K citations

    81

    h-index

  2. Hepatology

    88 publications · 10.6K citations

    58

    h-index

  3. PubMed

    Repository · 307 publications · 10.3K citations

    50

    h-index

  4. Cancer

    98 publications · 5K citations

    44

    h-index

  5. Journal of Hepatology

    58 publications · 2.8K citations

    31

    h-index

1–5